Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease

Movement Disorders

Volumn 30, Issue 2, 2015, Pages 141-149

  Napier, T Celeste ^a   Corvol, Jean Christophe ^b   Grace, Anthony A ^c   Roitman, Jamie D ^d   Rowe, James ^e   Voon, Valerie ^e   Strafella, Antonio P ^f  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

6 OHDA; Basal ganglia; Dopamine agonists; FMRI; Imaging; l dopa; PET; Pramipexole; Prefrontal cortex

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

BRAIN ELECTROPHYSIOLOGY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMPULSE CONTROL DISORDER; IMPULSIVENESS; NEUROANATOMY; NEUROPATHOLOGY; NEUROSCIENCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DRUG EFFECTS; GENETICS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DOPAMINE AGONISTS; HUMANS; IMPULSIVE BEHAVIOR; PARKINSON DISEASE;

EID: 84922255548     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26068     Document Type: Review

References (90)

1. Weintraub D, Papey K, Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease. Neurology 2013;80:176-180.
2. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
3. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011;69:986-996.
4. Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser JP. Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 2010;35:2155-2164.
5. Djamshidian A, Sanotsky Y, Matviyenko Y, et al. Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism. Addiction 2013;108:771-779.
6. Voon V, Gao J, Brezing C, et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011;134:1438-1446.
7. Djamshidian A, O'Sullivan SS, Wittmann BC, Lees AJ, Averbeck BB. Novelty seeking behaviour in Parkinson's disease. Neuropsychologia 2011;49:2483-2488.
8. Averbeck BB, Djamshidian A, O'Sullivan SS, Housden CR, Roiser JP, Lees AJ. Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease. Behav Neurosci 2013;127:245-255.
9. Nombela C, Rittman T, Robbins TW, Rowe JB. Multiple modes of impulsivity in Parkinson's disease. PLoS ONE 2014;9:e85747.
10. Obeso I, Wilkinson L, Casabona E, et al. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res 2011;212:371-384.
11. Voon V, Reynolds B, Brezing C, et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl) 2010;207:645-659.
12. Decamp E, Schneider JS. Effect of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys. Eur J Neurosci 2006;24:2098-2104.
13. Tedford SE, Persons AL, Napier TC. Lesions of the dorsolateral striatum increase delay discounting in a rat model of impulsive choice using intracranial self-stimulation. 2014; under review.
14. Meck WH, Benson AM. Dissecting the brain's internal clock: how frontal-striatal circuitry keeps time and shifts attention. Brain and Cognition 2002;48:195-211.
15. Rokosik SL, Napier TC. Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls. Neuropsychopharmacology 2012;37:1397-1408.
16. Buckholtz JW, Treadway MT, Cowan RL, et al. Dopaminergic network differences in human impulsivity. Science 2010;329:532.
17. Steeves TDL, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132:1376-1385.
18. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis 2010;39:98-104.
19. Ray N, Miyasaki JM, Zurowski M, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study Neurobiol Dis 2012;48:519-525.
20. Vriend C, Nordbeck AH, Booji J, et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Mov Disord 2014;29:904-911.
21. van Eimeren T, Pellecchia G, Cilia R, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010;5:1711-1716.
22. Cilia R, Cho SS, van Eimeren T, Marotta G, et al. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. Mov Disord 2011;26:225-333.
23. Ray NJ, Strafella AP. Imaging impulse control disorders in Parkinson's disease and their relationship to addiction. J Neural Transm 2013;120:659-664.
24. Antonelli F, Ko JH, Miyasaki J, et al. Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. Hum Brain Mapp 2014;35:2499-2506.
25. Ballanger B, van Eimeren T, Moro E, et al. Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol 2009;66:817-824.
26. Djamshidian A, Jha A, O'Sullivan SS, et al. Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov Disord 2010;25:2203-2210.
27. Rao H, Mamikonyan E, Detre JA, Siderowf AD, Stern MB, Potenza MN, Weintraub D. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord 2010;25:1660-1669.
28. Gauggel S, Rieger M, Feghoff TA. Inhibition of ongoing responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:539-544.
29. Furl N, Averbeck BB. Parietal cortex and insula relate to evidence seeking relevant to reward-related decisions. J Neurosci 2011;31:17572-17582.
30. Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC. Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 2011;18:703-710.
31. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010;40:216-221.
32. Rae CL, Correia MM, Altena E, et al. White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 2012;62:1675-1684.
33. Homberg JR, Pattij T, Janssen MC, et al. Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility. Eur J Neurosci 2007;26:2066-2073.
34. Del-Ben CM, Deakin JF, McKie S, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 2005;30:1724-1734.
35. Macoveanu J, Hornboll B, Elliott R, et al. Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition. Neuropsychopharmacology 2013;38:996-1005.
36. Robinson ES, Dalley JW, Theobald DE, et al. Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 2008;33:2398-2406.
37. Rubia K, Lee F, Cleare AJ, et al. Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI. Psychopharmacology (Berl) 2005;179:791-803.
38. Harrison AA, Everitt BJ, Robbins TW. Central serotonin depletion impairs both the acquisition and performance of a symmetrically reinforced go/no-go conditional visual discrimination. Behav Brain Res 1999;100:99-112.
39. Vollm B, Richardson P, McKie S, Elliott R, Deakin JF, Anderson IM. Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. Eur J Neurosci 2006;23:552-560.
40. Bari A, Eagle DM, Mar AC, Robinson ES, Robbins TW. Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. Psychopharmacology (Berl) 2009;205:273-283.
41. Bari A, Mar AC, Theobald DE, et al. Prefrontal and monoaminergic contributions to stop-signal task performance in rats. J Neurosci 2011;31:9254-9263.
42. Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2007;62:977-984.
43. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2006;311:861-863.
44. Ye Z, Altena E, Nombela C, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain 2014;137:1145-1155.
45. Ye Z, Altena E, Nombela C, et al. Improving impulsivity in Parkinson's disease with atomoxetine. Biol Psychiatry 2014. DOI: 10.1016/j.biopsych.2014.01.024.
46. Ye Z, Nombela C, Ham T, et al. Predictive modelling of Atomoxetine and Citalopram's effects on response inhibition in Parkinson's disease in Organization of Human Brain Mapping annual meeting, 2014: Hamburg. Poster #445.
47. Carelli RM. Nucleus accumbens cell firing and rapid dopamine signaling during goal-directed behaviors in rats. Neuropharmacology 2004;47[Suppl 1]:180-189.
48. Carelli RM, Wightman RM. Functional microcircuitry in the accumbens underlying drug addiction: insights from real-time signaling during behavior. Curr Opin Neurobiol 2004;14:763-768.
49. Schultz W. Behavioral dopamine signals. Trends Neurosci 2007;30:203-210.
50. Goto Y, Grace AA. Limbic and cortical information processing in the nucleus accumbens. Trends Neurosci 2008;31:552-558.
51. Ghahremani DG, Lee B, Robertson CL, et al. Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci 2012;32:7316-7324.
52. Rao H, Korczykowski M, Pluta J, Hoang A, Detre JA. Neural correlates of voluntary and involuntary risk taking in the human brain: an fMRI Study of the Balloon Analog Risk Task (BART). Neuroimage 2008;42:902-910.
53. Claassen DO, van den Wildenberg WP, Ridderinkhof KR, Jessup CK, Harrison MB, Wooten GF, Wylie SA. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci 2011;125:492-500.
54. Aron AR, Poldrack RA. Cortical and subcortical contributions to Stop signal response inhibition: role of the subthalamic nucleus. J Neurosci 2006;26:2424-2433.
55. Li CS, Yan P, Sinha R, Lee TW. Subcortical processes of motor response inhibition during a stop signal task. Neuroimage 2008;41:1352-1363.
56. Moustafa AA, Cohen MX, Sherman SJ, Frank MJ. A role for dopamine in temporal decision making and reward maximization in parkinsonism. J Neurosci 2008;28:12294-12304.
57. Roitman JD, Loriaux AL. Nucleus accumbens responses differentiate execution and restraint in reward-directed behavior. J Neurophysiol 2014;111:350-360.
58. Cui G, Jun SB, Jin X, Pham MD, Vogel SS, Lovinger DM, Costa RM. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 2013;494:238-242.
59. Napier TC. Contribution of the amygdala and nucleus accumbens to ventral pallidal responses to dopamine agonists. Synapse 1992;10:110-119.
60. Zigmond MJ, Berger TW, Grace AA, Stricker EM. Compensatory responses to nigrostriatal bundle injury: studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol Chem Neuropathol 1989;10:185-200.
61. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296.
62. Hollerman JR, Grace AA. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Research 1990;533:203-212.
63. Harden DG, Grace AA. Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment. J Neurosci 1995;15:6157-6166.
64. Lodge DJ, Grace AA. Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. J Neurosci 2008;28:7876-7882.
65. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 1984;4:2866-2876.
66. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 1984;4:2877-2890.
67. Schultz W. The phasic reward signal of primate dopamine neurons. Adv Pharmacol 1998;42:686-690.
68. Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology 2006;31:1356-1361.
69. Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007;30:220-227.
70. Goto Y, Grace AA Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nature-Neuroscience 2005;8:805-812.
71. Goto Y, Grace AA. Dopamine-depndent interactions between limbic and prefrontal cortical plasticity in the nucleus accumbens: disruption by cocaine sensitization. Neuron 2005;47:255-266.
72. Maren S. Neurotoxic or electrolytic lesions of the ventral subiculum produce deficits in the acquisition and expression of Pavlovian fear conditioning in rats. Behav Neurosci 1999;113:283-290.
73. Fanselow MS. Contextual fear, gestalt memories, and the hippocampus. Behav Brain Res 2000;110:73-81.
74. Sesack SR, Grace AA. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010;35:27-47.
75. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD, Lees AJ. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
76. Sesia T, Bizup B, Grace AA. Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity. Int J Neuropsychopharmacol 2013;16:1295-1307.
77. Henry DJ, Hu XT, White FJ. Adaptations in the mesoaccumbens dopamine system resulting from repeated administration of dopamine D1 and D2 receptor-selective agonists: relevance to cocaine sensitization. Psychopharmacology (Berl) 1998;140:233-242.
78. Karkowski LM, Prescott CA, Kendler KS. Multivariate assessment of factors influencing illicit substance use in twins from female-female pairs. Am J Med Genet 2000;96:665-670.
79. Black DW, Moyer T. Clinical features and psychiatric comorbidity of subjects with pathological gambling behavior. Psychiatr Serv 1998;49:1434-1439.
80. Slutske WS, Eisen S, True WR, Lyons MJ, Goldberg J, Tsuang M. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry 2000;57:666-673.
81. Eisen SA, Lin N, Lyons MJ, et al. Familial influences on gambling behavior: an analysis of 3359 twin pairs. Addiction 1998;93:1375-1384.
82. Slutske WS, Zhu G, Meier MH, Martin NG. Genetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry 2010;67:624-630.
83. Comings DE, Gade-Andavolu R, Gonzalez N, et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 2001;60:107-116.
84. Cormier F, J Mueliner, J-C Corvol. Genetics of impusle control disorders in Parkinson's disease. J Neural Transm 2013;120:665-671.
85. Lind PA, Zhu G, Montgomery GW, et al. Genome-wide association study of a quantitative disordered gambling trait. Addict Biol 2013;18:511-522.
86. Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009;24:1803-1810.
87. Lee JY, Jeon BS, Kim HJ, Park SS. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat Disord 2012;18:76-78.
88. Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2012;18:397-399.
89. Santangelo G1, Barone P, Trojano L, Vitale C. Pathological gambling in Parkinson's disease. A comprehensive review. Parkinsonism Relat Disord. 2013;19:645-653.
90. Cilia R, van Eimeren T. Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct Funct 2011;216:289-299.